Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.

Wiese MD, Alotaibi N, O'Doherty C, Sorich MJ, Suppiah V, Cleland LG, Proudman SM.

Pharmacogenomics J. 2014 Aug;14(4):350-5. doi: 10.1038/tpj.2013.45. Epub 2014 Jan 7.

PMID:
24394199
2.

N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.

Kumagai S, Komada F, Kita T, Morinobu A, Ozaki S, Ishida H, Sano H, Matsubara T, Okumura K.

Pharm Res. 2004 Feb;21(2):324-9.

PMID:
15032315
3.

Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.

Yamasaki Y, Ieiri I, Kusuhara H, Sasaki T, Kimura M, Tabuchi H, Ando Y, Irie S, Ware J, Nakai Y, Higuchi S, Sugiyama Y.

Clin Pharmacol Ther. 2008 Jul;84(1):95-103. doi: 10.1038/sj.clpt.6100459. Epub 2008 Jan 2.

PMID:
18167504
4.
5.

Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis.

Zhang LL, Yang S, Wei W, Zhang XJ.

Pharmacogenet Genomics. 2014 Nov;24(11):531-8. doi: 10.1097/FPC.0000000000000085.

PMID:
25144752
6.

Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.

Wiese MD, Schnabl M, O'Doherty C, Spargo LD, Sorich MJ, Cleland LG, Proudman SM.

Arthritis Res Ther. 2012 Jul 12;14(4):R163. doi: 10.1186/ar3911.

PMID:
22784880
7.

Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis.

Wadelius M, Stjernberg E, Wiholm BE, Rane A.

Pharmacogenetics. 2000 Feb;10(1):35-41.

PMID:
10739170
8.

Prospective study of the association between NAT2 gene haplotypes and severe adverse events with sulfasalazine therapy in patients with rheumatoid arthritis.

Soejima M, Kawaguchi Y, Hara M, Kamatani N.

J Rheumatol. 2008 Apr;35(4):724. No abstract available.

PMID:
18398952
9.

Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.

James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, Proudman SM.

J Rheumatol. 2008 Apr;35(4):562-71. Epub 2008 Mar 1.

PMID:
18322994
10.

Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene.

Tanaka E, Taniguchi A, Urano W, Nakajima H, Matsuda Y, Kitamura Y, Saito M, Yamanaka H, Saito T, Kamatani N.

J Rheumatol. 2002 Dec;29(12):2492-9.

PMID:
12465141
11.

Pharmacogenomics in rheumatoid arthritis.

Ranganathan P.

Methods Mol Biol. 2008;448:413-35. doi: 10.1007/978-1-59745-205-2_14. Review.

PMID:
18370240
12.

Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis.

Soukup T, Dosedel M, Nekvindova J, Toms J, Vlcek J, Pavek P.

Clin Exp Rheumatol. 2015 May-Jun;33(3):426-32. Epub 2015 Jan 29. Review.

PMID:
25664505
13.

Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration.

Adkison KK, Vaidya SS, Lee DY, Koo SH, Li L, Mehta AA, Gross AS, Polli JW, Humphreys JE, Lou Y, Lee EJ.

J Pharm Sci. 2010 Feb;99(2):1046-62. doi: 10.1002/jps.21860.

PMID:
19569219
14.

Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs.

van der Heijden J, de Jong MC, Dijkmans BA, Lems WF, Oerlemans R, Kathmann I, Scheffer GL, Scheper RJ, Assaraf YG, Jansen G.

Ann Rheum Dis. 2004 Feb;63(2):131-7.

PMID:
14722200
15.

A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.

Choy EH, Smith C, Doré CJ, Scott DL.

Rheumatology (Oxford). 2005 Nov;44(11):1414-21. Epub 2005 Jul 19. Review.

PMID:
16030080
16.

Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort.

McWilliams DF, Kiely PD, Young A, Walsh DA.

BMC Musculoskelet Disord. 2013 May 1;14:153. doi: 10.1186/1471-2474-14-153.

PMID:
23634781
17.

[Pharmacogenetics of disease modifying anti-rheumatic drugs].

Taniguchi A, Urano W, Tanaka E, Akama H, Yamanaka H, Kamatani N.

Nihon Rinsho. 2002 Dec;60(12):2339-44. Japanese.

PMID:
12510359
18.

Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use.

Proudman SM, James MJ, Spargo LD, Metcalf RG, Sullivan TR, Rischmueller M, Flabouris K, Wechalekar MD, Lee AT, Cleland LG.

Ann Rheum Dis. 2015 Jan;74(1):89-95. doi: 10.1136/annrheumdis-2013-204145. Epub 2013 Sep 30.

PMID:
24081439
19.

Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.

Schoels M, Kapral T, Stamm T, Smolen JS, Aletaha D.

Ann Rheum Dis. 2007 Aug;66(8):1059-65. Epub 2007 Feb 16.

PMID:
17307765
20.

Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

Möttönen T, Hannonen P, Korpela M, Nissilä M, Kautiainen H, Ilonen J, Laasonen L, Kaipiainen-Seppänen O, Franzen P, Helve T, Koski J, Gripenberg-Gahmberg M, Myllykangas-Luosujärvi R, Leirisalo-Repo M; FIN-RACo Trial Group. FINnish Rheumatoid Arthritis Combination therapy..

Arthritis Rheum. 2002 Apr;46(4):894-8.

PMID:
11953964

Supplemental Content

Support Center